The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. (January 2023)

• Record Type: Journal Article
• Authors: VanLandingham, Nathan K.; Nazarenko, Andrew; Grandis, Jennifer R.; Johnson, Daniel E.
• Is Part Of: Advances in biological regulation. Volume 87(2023)
• Publication Date: 2023-01
• Subjects: PIK3CA -- Phosphoinositide 3-kinase alpha -- p110alpha -- Alpelisib; Cellular control mechanisms -- Periodicals; Biological control systems -- Periodicals; Molecular biology -- Periodicals; Periodicals; 571.74
• DOI: 10.1016/j.jbior.2022.100934
• Languages: English
• ISSNs: 2212-4926

Abstract

Abstract: Genetic alterations of the PIK3CA gene, encoding the p110α catalytic subunit of PI3Kα enzyme, are found in a broad spectrum of human cancers. Many cancer-associated PIK3CA mutations occur at 3 hotspot locations and are termed canonical mutations. Canonical mutations result in hyperactivation of PI3K and promote oncogenesis via the PI3K/AKT/mTOR and PI3K/COX-2/PGE2 signaling pathways. These mutations also may serve as predictive biomarkers of response to PI3K inhibitors, as well as NSAID therapy. A large number of non-canonical PIK3CA mutations have also been identified in human tumors, but their functional properties are poorly understood. Here we review the landscape of PIK3CA mutations in different cancers and efforts underway to define the functional properties of non-canonical PIK3CA mutations. In addition, we summarize what has been learned from clinical trials of PI3K inhibitors as well as current trials incorporating these molecular targeting agents.